By detecting the amplification of DRP1 and OPA1 in patients, the mortality and poor functional outcome of cognitive impairment and peripheral neuropathy in diabetes mellitus may be intervened as early as possible. This evidence concerns the gene OPA1 and peripheral neuropathy.